This article was originally published in The Gray Sheet
Executive SummaryRoche's $5.3 bil. acquisition of Syntex is completed Sept. 1 after Roche agrees to divest within a year the U.S. portion of Syntex' Syva diagnostics subsidiary. The Federal Trade Commission, which made its approval of the acquisition conditional on Roche's divestiture of Syva, said it was concerned that combining Roche and Syva's drugs of abuse testing businesses "could substantially lessen competition in" that market "or tend to create a monopoly...or enhance the likelihood of collusion in the market." Drug screening and monitoring assays are a major portion of Syva's business, which also includes infectious disease diagnostics and immunodiagnostics. Syva had sales of $212 mil. in 1993
You may also be interested in...
Senate Finance Committee’s approach to penalize companies for raising WAC list prices is not a ‘price control,’ but a reasonable approach to change the incentives that distort pricing in the supply chain, US HHS Secretary Alex Azar says.
With the pre-GDUFA backlog largely acted upon, the FDA expects ANDA approvals to decrease, but supplement actions to increase in FY 2020 and FY 2021.
February and March inspections deferred unless any are deemed mission critical. China director remains behind as staff evacuate.